BAlloon expandable vs. SElf expanding transcatheter vaLve for degenerated bioprosthesIs (BASELINE trial): A protocol update

Jun 27, 2026 by in CARDIOLOGY Comments Off on BAlloon expandable vs. SElf expanding transcatheter vaLve for degenerated bioprosthesIs (BASELINE trial): A protocol update
The objective of the BAlloon Expandable vs. Self-Expanding Transcatheter VaLve for Degenerated Bioprosthesis (BASELINE) trial is to compare the balloon-expandable SAPIEN/MYVAL transcatheter heart valve (THV) series with the self-expanding EVOLUT…
read more

Time-alignment considerations in evaluating AI-ECG–guided pulmonary valve replacement timing in repaired tetralogy of Fallot

Jun 27, 2026 by in CARDIOLOGY Comments Off on Time-alignment considerations in evaluating AI-ECG–guided pulmonary valve replacement timing in repaired tetralogy of Fallot
We read with great interest the report by Mayourian et al on the use of an artificial intelligence–enabled electrocardiogram (AI-ECG) to inform pulmonary valve replacement (PVR) timing in repaired tetralogy…
read more

Response to the letter: Time alignment considerations in evaluating AI-ECG guidance of pulmonary valve replacement timing in repaired tetralogy of Fallot

Jun 27, 2026 by in CARDIOLOGY Comments Off on Response to the letter: Time alignment considerations in evaluating AI-ECG guidance of pulmonary valve replacement timing in repaired tetralogy of Fallot
We thank Dr. Zablah and colleagues for their thoughtful comments on our study, which examines the use of artificial intelligence-enabled electrocardiogram (AI-ECG) to inform the timing of pulmonary valve replacement…
read more

Design and rationale of the Radial Access Insertion Sheath Evaluation via the electronic medical record (RAISE-EMR) study

Jun 27, 2026 by in CARDIOLOGY Comments Off on Design and rationale of the Radial Access Insertion Sheath Evaluation via the electronic medical record (RAISE-EMR) study
Highlights • EMR-based randomization can enable rapid enrollment in pragmatic clinical trials. • EMR embedded trials can proceed without significant clinical workflow interruptions. • Prelude Ideal (lower cost) did not…
read more

Evaluation of high intensity interval training in patients with a right ventricle to pulmonary artery conduit in a randomized controlled trial: Rationale and design of the “Right HIIT” study

Jun 27, 2026 by in CARDIOLOGY Comments Off on Evaluation of high intensity interval training in patients with a right ventricle to pulmonary artery conduit in a randomized controlled trial: Rationale and design of the “Right HIIT” study
Highlights • High intensity interval training is a promising method to enhance exercise capacity. • This study focuses on an understudied population of complex outflow tract disorders. • Heterogeneous outcome…
read more

CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics

Jun 27, 2026 by in CARDIOLOGY Comments Off on CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics
Highlights • Whether coronary calcium (CAC) better selects patients for statin therapy is unknown. • CorCal randomized 5,772 primary prevention patients to address this question. • The pooled cohort equation…
read more

Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial

Jun 27, 2026 by in CARDIOLOGY Comments Off on Vasodilation, loop diuretics, or their combination in acute heart failure: Rationale and design of the randomized placebo-controlled DECONGEST-AHF trial
Highlights • Randomized, double-blinded, placebo-controlled trial. • Compares loop diuretics, nitrates, or both as acute treatment of acute heart failure. • Interventions are initiated within 3 hours of hospital arrival….
read more

Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study

Jun 27, 2026 by in CARDIOLOGY Comments Off on Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study
Abstract Background Coronary vasospasm is highly prevalent in patients with angina and no obstructive coronary arteries (ANOCA). In the pathophysiology of coronary vasospasm, endothelial dysfunction and vascular smooth muscle cell…
read more
Get Clinical Tree app for offline access